Publicacions en què col·labora amb Juan Carlos Hernández Boluda (10)

2023

  1. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  2. Should we move to a genomic classification of neutrophilic myeloid neoplasms?

    Blood Advances

2022

  1. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

    Leukemia Research, Vol. 115

  2. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

    British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538

  3. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

2021

  1. The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

    Leukemia and Lymphoma

  2. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis

    Bone Marrow Transplantation, Vol. 56, Núm. 9, pp. 2160-2172

2020

  1. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

    Leukemia, Vol. 34, Núm. 10, pp. 2648-2659

2017

  1. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia

    British Journal of Haematology, Vol. 178, Núm. 5, pp. 764-771

2016

  1. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera

    European Journal of Haematology, Vol. 96, Núm. 3, pp. 285-290